Thousands of C. auris cases are being tracked across the U.S., and California is carrying the biggest share by far. The fungus is showing up most often in medical settings, where it can linger, spread quietly, and create a serious headache for vulnerable patients.
The CDC’s provisional count shows 3,437 clinical cases reported in 27 states through the week ending July 25. California alone has 873 cases, with Texas, Tennessee, Ohio, Georgia, Louisiana, Illinois, Arizona, Michigan, Virginia and Pennsylvania also posting notable numbers.
Candida auris is a yeast, but it behaves like a much bigger threat once it gets into hospitals and long-term care facilities. It can survive on surfaces for a long time and move from one patient to another through contaminated objects, including bedrails, doorknobs and shared medical equipment.
That ability to hang around makes it especially tough in places where people are already sick. Patients can carry it without symptoms, a situation known as colonization, which means the fungus can spread without drawing attention right away.
Not every clinical case means an active infection, and that distinction matters. Some specimens are collected during routine care, so a positive result can reflect colonization rather than a full-blown illness.
Still, the infection risk is not something to shrug off. The fungus can lead to invasive disease, including bloodstream infections, and those outcomes are most likely to hit people with serious underlying health problems.
Patients with breathing tubes, feeding tubes, IV lines or catheters face a higher risk, especially if they spend a long time in the hospital or are admitted repeatedly. For people without those risk factors, the chance of colonization or infection is much lower.
Experts say the concern goes beyond simple spread. Dr. Marc Siegel described C. auris as an “emerging problem of great concern,” pointing to how easily it can move through care environments and how difficult it can be to recognize early.
“It is resistant to multiple antifungal drugs, and it tends to spread in hospital settings, including on equipment being used on immunocompromised and semi-immunocompromised patients, such as ventilators and catheters,” he previously told Fox News Digital.
“Unfortunately, symptoms such as fever, chills and aches may be ubiquitous, and it can be mistaken for other infections.”
That confusion can buy the fungus time, and time is exactly what doctors do not want to lose. Invasive C. auris infections have been linked to mortality rates between 30% and 72%, though many affected patients are already seriously ill, making the picture harder to sort out.
The treatment challenge is another reason health officials are paying close attention. The CDC labels the fungus an “urgent antimicrobial-resistance threat” because it is often resistant to several antifungal drugs.
More than 90% of U.S. samples are resistant to fluconazole, one of the most common antifungal medications. Echinocandins are the main treatment option right now, but some strains can resist all three major antifungal classes.
That is why infection control remains such a big deal. Careful sterilization, strong disinfection practices and fast identification can help slow the fungus down, even as researchers work on better treatments and hospitals watch for new cases.
